Previous 10 | Next 10 |
2024-05-05 08:00:00 ET As Wall Street embarks on the first full week of May, a diverse group of companies is set to report financial results. Notable names include The Walt Disney Company ( NYSE: DIS ), Palantir Technologies ( NYSE: PLTR ), Realty Income ( NYSE: ...
End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ. Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants. ‘Notice of Guaranteed Delivery’ Is Available for Warrant Exercises. A...
2024-04-28 21:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants. Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today anno...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 2, 2024) - Faruqi & Faruqi, LLP, a leading national s...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 1, 2024) - Faruqi & Faruqi, LLP, a leading national s...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 27, 2024) - Faruqi & Faruqi, LLP, a leading national ...
2024-03-25 13:50:25 ET Summary Cassava Sciences, Inc. reported $121.1m of cash and a net loss of $(97.2m) for the year 2023. The company's research and development expenses increased to $89.4m in 2023. Cassava's CEO remains optimistic about the Phase 3 program of its drug cand...
2024-03-25 11:58:56 ET More on Cassava Sciences Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go? Cassava Sciences And Alzheimer's Disease: Opaque Clarity Biotech And Pharma Diversification Pays Off Cassava Sciences again under scrutin...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 25, 2024) - Faruqi & Faruqi, LLP, a leading national ...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
NYSE Market:
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.5% on Monday. Shares of GSK plc (NYSE:GSK) fell sharply in tod...
$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NE...
2024-05-08 16:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...